Last 30.50 GBp
Change Today -0.25 / -0.81%
Volume 231.2K
SPH On Other Exchanges
Symbol
Exchange
OTC US
London
Munich
As of 11:35 AM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

sinclair is pharma plc (SPH) Snapshot

Open
31.00 GBp
Previous Close
30.75 GBp
Day High
31.00 GBp
Day Low
29.75 GBp
52 Week High
01/13/14 - 34.00 GBp
52 Week Low
08/9/13 - 23.50 GBp
Market Cap
151.7M
Average Volume 10 Days
250.2K
EPS TTM
-0.03 GBp
Shares Outstanding
497.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SINCLAIR IS PHARMA PLC (SPH)

Related News

No related news articles were found.

sinclair is pharma plc (SPH) Related Businessweek News

No Related Businessweek News Found

sinclair is pharma plc (SPH) Details

Sinclair IS Pharma plc, a specialty pharmaceutical company, provides surface technology and delivery systems for aesthetics, wound care, and skin care treatments worldwide. The company’s aesthetic dermatology solutions include Kelo-cote, a topical silicone gel used for the management and prevention of hypertrophic and keloid scars; Kelo-Stretch, which helps in rebuilding damaged collagen and regaining skin elasticity; Sculptra, a volumizer designed to stimulate natural collagen growth; Perfectha for the treatment of wrinkles and facial contours; and Succeev hyaluronic acid fillers to treat various indications, such as wrinkles-filling, facial creases depressions reduction, and scar treatment. Its wound care products comprise Flammazine and Flammacerium that are used in the prevention and treatment of severe burns and wounds; and Aloclair Plus for relieving the pain caused by aphthous mouth ulcers and other minor oral lesions. The company’s skin care products include Atopiclair, a non-steroidal topical treatment for the symptomatic relief of atopic, contact allergic, and irritant dermatitis; Papulex, a dermocosmetic product used for cleansing, hydrating, and protecting acne prone skin; Sebclair for the management of skin and scalp seborrhoeic dermatitis; and Bio-Taches products for preventing and reducing pigmentation disorders, such as chloasma, melasma, or dyschromia. Further, it offers other products consisting of Variquel/Haemopressin for the treatment of bleeding oesophageal varices; Aloxi, a 2nd generation 5HT3 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting associated with highly emetogenic chemotherapy and moderately emetogenic chemotherapy; and Decapinol for plaque management. Sinclair IS Pharma plc offers its solutions to hospitals, plastic surgeons, dermatologists, and pharmacists. The company was founded in 1971 and is headquartered in London, the United Kingdom.

144 Employees
Last Reported Date: 10/15/13
Founded in 1971

sinclair is pharma plc (SPH) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: 815.0K GBP
Chief Operating Officer and Director
Total Annual Compensation: 559.0K GBP
Compensation as of Fiscal Year 2013.

sinclair is pharma plc (SPH) Key Developments

Sinclair IS Pharma plc, Special/Extraordinary Shareholders Meeting, May 01, 2014

Sinclair IS Pharma plc, Special/Extraordinary Shareholders Meeting, May 01, 2014., at 10:00 GMT Standard Time. Location: Reed Smith LLP, Broadgate Tower. Agenda: To authorize the Directors to allot relevant securities up to an aggregate nominal value of: £625,000.00 in connection with the placing; and (ii) £1,658,049.24 otherwise than in connection with the placing; and to disapply statutory pre-emption rights, provided that such authority shall be limited to, that is, the allotment of equity securities in connection with the placing, and otherwise the allotment of equity securities up to an aggregate nominal amount of £497,414.77.

Sinclair IS Pharma plc Reports Unaudited Consolidated Earnings Results for the Six Months Ended December 31, 2013

Sinclair IS Pharma plc reported unaudited consolidated earnings results for the six months ended December 31, 2013. For the period, the company reported revenue of £24,461,000 compared to £22,950,000 for the same period a year ago. Operating loss was £2,322,000 compared to £5,057,000 last year. Loss before taxation was £2,499,000 compared to £5,776,000 last year. Loss for the period from continuing operations was £2,356,000 or 0.5 pence per basic and diluted share compared to £5,183,000 or 1.2 pence per basic and diluted last year. Loss for the period was £3,400,000 or 0.8 pence per basic and diluted share compared to £5,183,000 or 1.2 pence per basic and diluted last year. Net cash generated from operating activities was £3,359,000 compared to £1,376,000 last year. Purchases of property, plant and equipment was £10,000 compared to £33,000 last year. Purchase of intangible assets was £176,000 against £7,642,000 a year ago. Adjusted EBITDA increased to £1,100,000 compared to £1,000,000 last year. Net debt stood at £9,100,000 at December 31, 2013, increased from £6,900,000 at June 30, 2013 as a result of the cash outflows in the period.

Sinclair IS Pharma plc to Report First Half, 2014 Results on Mar 25, 2014

Sinclair IS Pharma plc announced that they will report first half, 2014 results on Mar 25, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SPH:LN 30.50 GBp -0.25

SPH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SPH.
View Industry Companies
 

Industry Analysis

SPH

Industry Average

Valuation SPH Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.4x
Price/Book 1.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SINCLAIR IS PHARMA PLC, please visit www.sinclairispharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.